Access cutting-edge kidney cancer treatment through this clinical trial at a research site in Hackensack. Study-provided care at no cost to qualified participants.
Access kidney cancer specialists in Hackensack at no cost
This study follows strict safety protocols and ethical guidelines
All study-related kidney cancer treatment provided free
This study is a randomized, open label, multicenter Phase II trial to evaluate the efficacy and safety of botensilimab (a novel Fc enhanced Tree depleting anti-CTLA4) and balstilimab (a novel anti-PD1) relative to ipilimumab and nivolumab in treatment naïve patients with metastatic ccRCC. The study will plan to enroll 120 eligible patients randomized in a 2:1 fashion to Arm A and Arm B. Patients in all IMDC Risk Groups are included. This study utilizes a Simon's two stage design which is describ
Sponsor: Michael B. Atkins, MD
Check if you qualify for this kidney cancer clinical trial in Hackensack, NJ
If you're searching for kidney cancer treatment options in Hackensack, NJ, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Hackensack research site is actively enrolling participants for this clinical trial. You'll receive care from experienced kidney cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.